Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation
Yvette L. Kasamon(Johns Hopkins University), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Gary L. Rosner(Johns Hopkins University), Heather J. Symons(Johns Hopkins University), Leo Luznik(Johns Hopkins University), William Matsui(The University of Texas at Austin), Ivan Borrello(Tampa General Hospital), Kenneth R. Cooke(Johns Hopkins University), Marianna Zahurak(Bloomberg (United States)), Ephraim J. Fuchs(Johns Hopkins University), Richard F. Ambinder(Johns Hopkins University), Satish Shanbhag(Florida Cancer Specialists & Research Institute), Robert A. Brodsky(Johns Hopkins University), Carol Ann Huff(Sidney Kimmel Comprehensive Cancer Center), Douglas E. Gladstone(Northwell Health), Lode J. Swinnen(Johns Hopkins University), Javier Bolaños‐Meade(Johns Hopkins University)
Cited by 42
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k